Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.58 |
| ▸ | BRD4 | O60885 | 2/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23453398 | 1.00 | CRBN (0.58) | CRBNBRD4DDB1IKZF3PARP1 | |
| SCHEMBL23453409 | 0.87 | CRBN (0.59) | CRBNBRD4DDB1IKZF3PARP1 | |
| SCHEMBL29894574 | 0.87 | CRBN (0.59) | CRBNBRD4DDB1IKZF3PARP1 | |
| SCHEMBL23453410 | 0.84 | CRBN (0.55) | CRBNBRD4DDB1IKZF3PARP1 | |
| SCHEMBL24745182 | 0.84 | CRBN (0.55) | CRBNBRD4DDB1IKZF3PARP1 | |
| SCHEMBL31178044 | 0.84 | CRBN (0.55) | CRBNBRD4DDB1IKZF3PARP1 | |
| SCHEMBL23453403 | 0.84 | CRBN (0.55) | CRBNBRD4DDB1IKZF3 | |
| SCHEMBL23458427 | 0.83 | CRBN (0.53) | CRBNBRD4DDB1PARP1 | |
| SCHEMBL23453698 | 0.82 | CRBN (0.52) | CRBNBRD4DDB1IKZF3 | |
| SCHEMBL23453408 | 0.81 | CRBN (0.52) | CRBNBRD4DDB1IKZF3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343706-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S. A. (PL) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343706-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CRBN, CDR2, DRD2 | CRBN 1/4885BRD4 449/4885DDB1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.